Comparative proteomic profiling of pancreatic ductal adenocarcinoma cell lines

Molecules and Cells

Volumn 37, Issue 12, 2014, Pages 888-898

  Kim, Yikwon ^a   Han, Dohyun ^a   Min, Hophil ^a   Jin, Jonghwa ^a   Yi, Eugene C ^b   Kim, Youngsoo ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Chemoresistance; Gemcitabine; LC MS MS; Pancreatic cancer; Quantitative proteomics

Indexed keywords

BETA 1 CATENIN; BETA CATENIN; BINDING PROTEIN; BIOLOGICAL MARKER; CYSTEINE; FIBROBLAST GROWTH FACTOR BINDING PROTEIN 1; FILAMIN; FILAMIN BETA; GEMCITABINE; GLUTATHIONE; IQ MOTIF CONTAINING GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 1; METHIONINE; PROTEIN; STAT3 PROTEIN; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN; DEOXYCYTIDINE; TUMOR MARKER;

ADENOCARCINOMA CELL LINE; ARTICLE; BIOINFORMATICS; CANCER RESISTANCE; CONTROLLED STUDY; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GLUTATHIONE METABOLISM; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; PANCREAS ADENOCARCINOMA; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; STATISTICAL ANALYSIS; TANDEM MASS SPECTROMETRY; TUMOR CELL LINE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MASS SPECTROMETRY; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR; PROCEDURES;

BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; CELL LINE, TUMOR; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE; HUMANS; MASS SPECTROMETRY; PANCREATIC NEOPLASMS; PROTEOMICS;

EID: 84936947467     PISSN: 10168478     EISSN: 02191032     Source Type: Journal    
DOI: 10.14348/molcells.2014.0207     Document Type: Article

References (62)

1. Arao, S., Masumoto, A., and Otsuki, M. (2000). Beta1 integrins play an essential role in adhesion and invasion of pancreatic carcinoma cells. Pancreas 20, 129-137.
2. Arumugam, T., Ramachandran, V., Fournier, K.F., Wang, H., Marquis, L., Abbruzzese, J.L., Gallick, G.E., Logsdon, C.D., McConkey, D.J., and Choi, W. (2009). Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 69, 5820-5828.
3. Bailey, K.M., and Liu, J. (2008). Caveolin-1 up-regulation during epithelial to mesenchymal transition is mediated by focal adhesion kinase. J. Biol. Chem. 283, 13714-13724.
4. Buchholz, M., Braun, M., Heidenblut, A., Kestler, H.A., Kloppel, G., Schmiegel, W., Hahn, S.A., Luttges, J., and Gress, T.M. (2005). Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 24, 6626-6636.
5. Burris, H.A., 3rd, Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., Cripps, M.C., Portenoy, R.K., Storniolo, A.M., Tarassoff, P., et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 15, 2403-2413.
6. Cao, H., Le, D., and Yang, L.X. (2013). Current status in chemotherapy for advanced pancreatic adenocarcinoma. Anticancer Res. 33, 1785-1791.
7. Carmichael, J., Fink, U., Russell, R.C., Spittle, M.F., Harris, A.L., Spiessi, G., and Blatter, J. (1996). Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer 73, 101-105.
8. Cavallaro, U., and Christofori, G. (2004). Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer 4, 118-132.
9. Chen, R., Yi, E.C., Donohoe, S., Pan, S., Eng, J., Cooke, K., Crispin, D.A., Lane, Z., Goodlett, D.R., Bronner, M.P., et al. (2005). Pancreatic cancer proteome: the proteins that underlie invasion, metastasis, and immunologic escape. Gastroenterology 129, 1187-1197.
10. Chen, Y.W., Liu, J.Y., Lin, S.T., Li, J.M., Huang, S.H., Chen, J.Y., Wu, J.Y., Kuo, C.C., Wu, C.L., Lu, Y.C., et al. (2011). Proteomic analysis of gemcitabine-induced drug resistance in pancreatic cancer cells. Mol. BioSyst. 7, 3065-3074.
11. Cheung, H.W., Cowley, G.S., Weir, B.A., Boehm, J.S., Rusin, S., Scott, J.A., East, A., Ali, L.D., Lizotte, P.H., Wong, T.C., et al. (2011). Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc. Natl. Acad. Sci. USA 108, 12372-12377.
12. Choudhary, C., and Mann, M. (2010). Decoding signalling networks by mass spectrometry-based proteomics. Nat. Rev. 11, 427-439.
13. Deer, E.L., Gonzalez-Hernandez, J., Coursen, J.D., Shea, J.E., Ngatia, J., Scaife, C.L., Firpo, M.A., and Mulvihill, S.J. (2010). Phenotype and genotype of pancreatic cancer cell lines. Pancreas 39, 425-435.
14. Fonslow, B.R., Stein, B.D., Webb, K.J., Xu, T., Choi, J., Park, S.K., and Yates, J.R., 3rd. (2013). Digestion and depletion of abundant proteins improves proteomic coverage. Nat. Methods 10, 54-56.
15. Fryer, R.A., Barlett, B., Galustian, C., and Dalgleish, A.G. (2011). Mechanisms underlying gemcitabine resistance in pancreatic cancer and sensitisation by the iMiD lenalidomide. Anticancer Res. 31, 3747-3756.
16. Furukawa, T., Duguid, W.P., Rosenberg, L., Viallet, J., Galloway, D.A., and Tsao, M.S. (1996). Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am. J. Pathol. 148, 1763-1770.
17. Griffith, O.W. (1999). Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic. Biol. Med. 27, 922-935.
18. Gronborg, M., Kristiansen, T.Z., Iwahori, A., Chang, R., Reddy, R., Sato, N., Molina, H., Jensen, O.N., Hruban, R.H., Goggins, M.G., et al. (2006). Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol. Cell. Proteomics 5, 157-171.
19. Gstaiger, M., and Aebersold, R. (2009). Applying mass spectrometry- based proteomics to genetics, genomics and network biology. Nat. Revi. Genet. 10, 617-627.
20. Han, D., Moon, S., Kim, H., Choi, S.E., Lee, S.J., Park, K.S., Jun, H., Kang, Y., and Kim, Y. (2011). Detection of differential proteomes associated with the development of type 2 diabetes in the Zucker rat model using the iTRAQ technique. J. Proteome Res. 10, 564-577.
21. Han, D., Moon, S., Kim, Y., Ho, W.K., Kim, K., Kang, Y., Jun, H., and Kim, Y. (2012). Comprehensive phosphoproteome analysis of INS-1 pancreatic beta-cells using various digestion strategies coupled with liquid chromatography-tandem mass spectrometry. J. Proteome Res. 11, 2206-2223.
22. Hruban, R.H., Goggins, M., Parsons, J., and Kern, S.E. (2000). Progression model for pancreatic cancer. Clin. Cancer Res. 6, 2969-2972.
23. Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protocols 4, 44-57.
24. Huanwen, W., Zhiyong, L., Xiaohua, S., Xinyu, R., Kai, W., and Tonghua, L. (2009). Intrinsic chemoresistance to gemcitabine is associated with constitutive and laminin-induced phosphorylation of FAK in pancreatic cancer cell lines. Mol. Cancer 8, 125.
25. Jameson, K.L., Mazur, P.K., Zehnder, A.M., Zhang, J., Zarnegar, B., Sage, J., and Khavari, P.A. (2013). IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors. Nat. Med. 19, 626-630.
26. Jones, S., Zhang, X., Parsons, D.W., Lin, J.C., Leary, R.J., G G Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008). Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806.
27. Juuti, A., Nordling, S., Lundin, J., Louhimo, J., and Haglund, C. (2005). Syndecan-1 expression--a novel prognostic marker in pancreatic cancer. Oncology 68, 97-106.
28. Kalluri, R., and Weinberg, R.A. (2009). The basics of epithelial- mesenchymal transition. J. Clin. Invest. 119, 1420-1428.
29. Kuramitsu, Y., Taba, K., Ryozawa, S., Yoshida, K., Zhang, X., Tanaka, T., Maehara, S., Maehara, Y., Sakaida, I., and Nakamura, K. (2010). Identification of up- and down-regulated proteins in gemcitabine-resistant pancreatic cancer cells using two-dimensional gel electrophoresis and mass spectrometry. Anticancer Res. 30, 3367-3372.
30. Kuramitsu, Y., Wang, Y., Taba, K., Suenaga, S., Ryozawa, S., Kaino, S., Sakaida, I., and Nakamura, K. (2012). Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells. Anticancer Res. 32, 2295-2299.
31. Li, D., Xie, K., Wolff, R., and Abbruzzese, J.L. (2004). Pancreatic cancer. Lancet 363, 1049-1057.
32. Lo, M., Ling, V., Wang, Y.Z., and Gout, P.W. (2008). The xc cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br. J. Cancer 99, 464-472.
33. Locasale, J.W. (2013). Serine, glycine and one-carbon units:cancer metabolism in full circle. Nat. Rev. Cancer 13, 572-583.
34. Makawita, S., Smith, C., Batruch, I., Zheng, Y., Ruckert, F., Grutzmann, R., Pilarsky, C., Gallinger, S., and Diamandis, E.P. (2011). Integrated proteomic profiling of cell line conditioned media and pancreatic juice for the identification of pancreatic cancer biomarkers. Mol. Cell. Proteomics 10, M111 008-599.
35. Mercurio, A.M., Rabinovitz, I., and Shaw, L.M. (2001). The alpha 6 beta 4 integrin and epithelial cell migration. Curr. Opin. Cell Biol. 13, 541-545.
36. Min, H., Han, D., Kim, Y., Cho, J.Y., Jin, J., and Kim, Y. (2014). Label-free quantitative proteomics and N-terminal analysis of human metastatic lung cancer cells. Mol. Cells 37, 457-466.
37. Mori-Iwamoto, S., Kuramitsu, Y., Ryozawa, S., Mikuria, K., Fujimoto, M., Maehara, S., Maehara, Y., Okita, K., Nakamura, K., and Sakaida, I. (2007). Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int. J. Oncol. 31, 1345-1350.
38. Mori-Iwamoto, S., Kuramitsu, Y., Ryozawa, S., Taba, K., Fujimoto, M., Okita, K., Nakamura, K., and Sakaida, I. (2008). A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Mol. Med. Rep. 1, 429-434.
39. Pavelka, N., Fournier, M.L., Swanson, S.K., Pelizzola, M., Ricciardi- Castagnoli, P., Florens, L., and Washburn, M.P. (2008). Statistical similarities between transcriptomics and quantitative shotgun proteomics data. Mol. Cell. Proteomics 7, 631-644.
40. Poland, J., Urbani, A., Lage, H., Schnolzer, M., and Sinha, P. (2004). Study of the development of thermoresistance in human pancreatic carcinoma cell lines using proteome analysis. Electrophoresis 25, 173-183.
41. Pramanik, K.C., Boreddy, S.R., and Srivastava, S.K. (2011). Role of mitochondrial electron transport chain complexes in capsaicin mediated oxidative stress leading to apoptosis in pancreatic cancer cells. PLoS One 6, e20151.
42. Radulovich, N., Qian, J.Y., and Tsao, M.S. (2008). Human pancreatic duct epithelial cell model for KRAS transformation. Methods Enzymol. 439, 1-13.
43. Rathos, M.J., Joshi, K., Khanwalkar, H., Manohar, S.M., and Joshi, K.S. (2012). Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers. J. Transl. Med. 10, 161.
44. Reynolds, A.B., Daniel, J., McCrea, P.D., Wheelock, M.J., Wu, J., and Zhang, Z. (1994). Identification of a new catenin: the tyrosine kinase substrate p120cas associates with E-cadherin complexes. Mo. Cell. Biol. 14, 8333-8342.
45. Samuel, N., and Hudson, T.J. (2012). The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat. Rev. Gastroenterol. Hepatol. 9, 77-87.
46. Sato, N., Fukushima, N., Maitra, A., Iacobuzio-Donahue, C.A., van Heek, N.T., Cameron, J.L., Yeo, C.J., Hruban, R.H., and Goggins, M. (2004). Gene expression profiling identifies genes associated with invasive intraductal papillary mucinous neoplasms of the G pancreas. Am. J. Pathol. 164, 903-914.
47. Sato, J., Kimura, T., Saito, T., Anazawa, T., Kenjo, A., Sato, Y., Tsuchiya, T., and Gotoh, M. (2011). Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma. J. Hepatobiliary Pancreat. Sci. 18, 700-711.
48. Seike, M., Kondo, T., Fujii, K., Yamada, T., Gemma, A., Kudoh, S., and Hirohashi, S. (2004). Proteomic signature of human cancer cells. Proteomics 4, 2776-2788.
49. Singh, A., and Settleman, J. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751.
50. Stergachis, A.B., MacLean, B., Lee, K., Stamatoyannopoulos, J.A., and MacCoss, M.J. (2011). Rapid empirical discovery of optimal peptides for targeted proteomics. Nat. Methods 8, 1041-1043.
51. Swaney, D.L., Wenger, C.D., and Coon, J.J. (2010). Value of using multiple proteases for large-scale mass spectrometry-based proteomics. J. Proteome Res. 9, 1323-1329.
52. Thiery, J.P., Acloque, H., Huang, R.Y., and Nieto, M.A. (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890.
53. Thu, K.L., Radulovich, N., Becker-Santos, D.D., Pikor, L.A., Pusic, A., Lockwood, W.W., Lam, W.L., and Tsao, M.S. (2014). SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/beta-catenin signaling. Oncogene 33, 279-288.
54. Tuveson, D.A., and Neoptolemos, J.P. (2012). Understanding metastasis in pancreatic cancer: a call for new clinical approaches. Cell 148, 21-23.
55. Voulgari, A., and Pintzas, A. (2009). Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and 898 Mol. Cells G G strategies to overcome drug resistance in the clinic. Biochim. Biophysica Acta 1796, 75-90.
56. Wei, S., Gao, X., Du, J., Su, J., and Xu, Z. (2011). Angiogenin enhances cell migration by regulating stress fiber assembly and focal adhesion dynamics. PLoS One 6, e28797.
57. Wisniewski, J.R., Zougman, A., Nagaraj, N., and Mann, M. (2009). Universal sample preparation method for proteome analysis. Nat. Methods 6, 359-362.
58. Wisniewski, J.R., Ostasiewicz, P., and Mann, M. (2011). High recovery FASP applied to the proteomic analysis of microdissected formalin fixed paraffin embedded cancer tissues retrieves known colon cancer markers. J. Proteome Res. 10, 3040-3049.
59. Yu, K.H., Barry, C.G., Austin, D., Busch, C.M., Sangar, V., Rustgi, A.K., and Blair, I.A. (2009). Stable isotope dilution multidimensional liquid chromatography-tandem mass spectrometry for pancreatic cancer serum biomarker discovery. J. Proteome Res. 8, 1565-1576.
60. Zhang, Y., Wen, Z., Washburn, M.P., and Florens, L. (2010). Refinements to label free proteome quantitation: how to deal with peptides shared by multiple proteins. Anal. Chem. 82, 2272-2281.
61. Zhou, J., and Du, Y. (2012). Acquisition of resistance of pancreatic cancer cells to 2-methoxyestradiol is associated with the upregulation of manganese superoxide dismutase. Mol. Cancer Res. 10, 768-777.
62. Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S.A., Triola, G., Wittinghofer, A., Bastiaens, P.I., et al. (2013). Small molecule inhibition of the KRAS- PDEdelta interaction impairs oncogenic KRAS signalling. Nature 497, 638-642.